UBS Group’s G1 Therapeutics GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-87,637
Closed -$200K – 10342
2024
Q2
$200K Buy
87,637
+87,329
+28,354% +$334K ﹤0.01% 5659
2024
Q1
$1.33K Sell
308
-2,872
-90% -$10K ﹤0.01% 8159
2023
Q4
$9.7K Buy
3,180
+2,967
+1,393% +$5.58K ﹤0.01% 7474
2023
Q3
$307 Sell
213
-2,501
-92% -$4.84K ﹤0.01% 8597
2023
Q2
$6.76K Sell
2,714
-3,587
-57% -$9.8K ﹤0.01% 7340
2023
Q1
$16.9K Sell
6,301
-1,682
-21% -$8.08K ﹤0.01% 7207
2022
Q4
$43.3K Sell
7,983
-48,000
-86% -$402K ﹤0.01% 6899
2022
Q3
$700K Buy
55,983
+55,770
+26,183% +$637K ﹤0.01% 4050
2022
Q2
$1K Sell
213
-222,706
-100% -$1.23M ﹤0.01% 10036
2022
Q1
$1.69M Sell
222,919
-34,800
-14% -$330K ﹤0.01% 3597
2021
Q4
$2.63M Buy
257,719
+137,157
+114% +$1.75M ﹤0.01% 3490
2021
Q3
$1.62M Buy
120,562
+105,274
+689% +$1.72M ﹤0.01% 3766
2021
Q2
$335K Sell
15,288
-51,183
-77% -$1.14M ﹤0.01% 5009
2021
Q1
$1.6M Buy
66,471
+66,258
+31,107% +$1.54M ﹤0.01% 3789
2020
Q4
$4K Sell
213
-5,000
-96% -$74.7K ﹤0.01% 7940
2020
Q3
$60K Buy
5,213
+3,648
+233% +$60.2K ﹤0.01% 5512
2020
Q2
$38K Sell
1,565
-9,161
-85% -$151K ﹤0.01% 6106
2020
Q1
$118K Sell
10,726
-16,684
-61% -$312K ﹤0.01% 5145
2019
Q4
$725K Sell
27,410
-39,261
-59% -$918K ﹤0.01% 4510
2019
Q3
$1.52M Buy
66,671
+49,598
+291% +$1.56M ﹤0.01% 3575
2019
Q2
$524K Buy
17,073
+16,360
+2,295% +$344K ﹤0.01% 4258
2019
Q1
$12K Sell
713
-93,428
-99% -$1.77M ﹤0.01% 6703
2018
Q4
$1.8M Buy
94,141
+86,380
+1,113% +$3.24M ﹤0.01% 3135
2018
Q3
$406K Buy
7,761
+5,568
+254% +$304K ﹤0.01% 4558
2018
Q2
$95K Buy
2,193
+1,093
+99% +$46.8K ﹤0.01% 5484
2018
Q1
$40K Sell
1,100
-254
-19% -$6.78K ﹤0.01% 5887
2017
Q4
$27K Buy
1,354
+954
+239% +$20.5K ﹤0.01% 6334
2017
Q3
$10K Sell
400
-495
-55% -$9.14K ﹤0.01% 6901
2017
Q2
$15K Buy
+895
New +$15.7K ﹤0.01% 6501

UBS Group's GTHX Position: Q3 2024 in Review

UBS Group sold out of G1 Therapeutics (GTHX) in Q3 2024, closing a stake of 87,637 shares — an estimated $200K sold.

UBS Group first reported a position in GTHX in Q2 2017 and held it in 29 quarters. The position peaked at $2.63M in Q4 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • UBS Group reported no remaining G1 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • UBS Group sold 87,637 G1 Therapeutics shares in Q3 2024, an estimated $200K.
  • UBS Group first reported a position in G1 Therapeutics in Q2 2017 and held it in 29 quarters.
  • UBS Group's G1 Therapeutics position peaked at $2.63M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.